SUGAR-seq, a single-cell method developed by researchers in Australia, is a first step towards analyzing differences in glycosylation in various cell types.
A federal court ruled this week that IonPath's MIBIscope does not infringe on Fluidigm's technology, though the company has indicated it will likely appeal.
The proteomics firm is expected to receive $514 million in proceeds through the deal, including a $425 million private investment in public equity (PIPE) transaction.
In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.
This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.
This webinar will discuss a study that sought to identify early biomarkers for cancer by analyzing pre-diagnosis samples from seemingly healthy individuals who were later diagnosed with cancer.
